Article | January 12, 2022

BioPharma's New Future: Genomic Medicine And The Tools That Will Help Us Realize Its Potential

Source: Cytiva

In a pandemic that has taken millions of lives, the emergency use authorization of the Pfizer-BioNTech and Moderna vaccines in 2020 was undoubtedly a critical milestone. For scientists and researchers studying what they have believed for decades to be the limitless potential of RNA-based therapeutics, it has also marked a major victory.

These sophisticated medicines can help address a wide range of medical needs, either by “silencing” disease-causing genes in areas of treatment previously considered “undruggable” by small molecules or proteins, or by delivering instructions for protein production within a cell that triggers an immune response, such as with the COVID-19 vaccines.

The journey to this tipping point has been a slow burn. But there is now an explosion of opportunity for any company interested in pursuing the development of these transformative medicines created by new technologies and collaborations driving the democratization of RNA therapeutics.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene